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The two phyto-oestrogens genistein and quercetin have been
reported to play a role in diet-related cancer risk and have recently
attracted research interest for their potential chemopreventive
activity (Setchell and Adlercreutz, 1988; Adlercreutz, 1990).
Genistein, but not quercetin, is structurally similar to 17b-oestra-
diol. A number of studies (Lock, 1991; Adlercreutz et al, 1995) have
proposed that the low incidence of breast cancer and the mild
menopause-related symptoms observed in Asian women (Ross et al,
1991) may be linked to the weak oestrogenic activity of genistein,
which is prevalently contained in soy beans and its derivatives.
Genistein has also received particular attention due to its oestrogenic
and antiproliferative properties in animal models (Barnes et al,
1990; Lamartiniere et al, 1995) as well as in vitro models
(Yamagihara et al, 1993; Barnes, 1995; Zava and Duwe, 1997).
Quercetin is contained in most edible fruits and vegetables
(Kühnau, 1976) and has been shown to exert growth inhibitory
activity on human breast (Scambia et al, 1993; Singhal et al,
1995), ovarian (Scambia et al, 1990), leukaemic (Larocca et al,
1990) and colon (Shiu-Ming Kuo, 1996) cancer cells.
Many different mechanisms of action have been proposed to
explain the growth-inhibitory activity of such phyto-oestrogens,
such as direct inhibition of tyrosine kinase activity (Akiyama et al,
1987), interaction with oestrogen receptor (ER) or with type-II
oestrogen binding sites (Martin et al, 1978), and inhibition of
DNA-topoisomerase II (Markovits et al, 1989). Most of the
proposed cellular targets for phyto-oestrogens are directly or indi-
rectly related to cell proliferation and may explain the growth-
inhibitory effects of such molecules, as well as the cell growth-
stimulatory activity presumably linked to the oestrogenic properties
of phyto-oestrogens. However, the exact mechanism underlying the
in vivo antiproliferative effect as well as the growth-stimulatory
activity, which has been observed only in ER-positive cell lines
(Fioravanti et al, 1998), has not yet been clarified.
In the present study, we compared in a typically oestrogen-
sensitive breast cancer cell line (MCF-7) the effects exerted by
genistein and by quercetin on oestrogen-mediated pathways in
order to gain insight into their mechanism at the molecular level.
The first part of the study addressed the effects of genistein and
quercetin on: (1) basal and stimulated growth of MCF-7 cells;
(2) steroid receptor modulation; and (3) expression of oestrogen-
regulated genes. In the second part, we focused on the molecular
mechanism underlying the different biocharacters (i.e. agonist/
antagonist) of the two phyto-oestrogens.
MATERIALS AND METHODS
Cell lines
MCF-7 cells (kindly provided by K Horwitz, University of
Colorado at Denver) were routinely maintained in DMEM/F12
(Sigma) without phenol red and supplemented with 2% fetal calf
serum (FCS) and 4 g l–1 glucose.
Cell growth experiments
Experiments were run in 24-well plates or in T-75 or T-150 flasks,
in DMEM/F12 supplemented with 2% FCS, in serum-free MOM3
medium (Cappelletti et al, 1993), or in DMEM/F12 supplemented
with 2% dextran-coated charcoal-stripped FCS (DCC-FCS) as
described by Soto and Sonnenschein (1985). Cell growth was
determined by total cell DNA evaluated directly in the 24 wells
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with the diphenylamine assay (Burton, 1956). Linearity between
cell number variations and DNA content of the wells was checked.
Steroid receptor determination
Cells (1 ´ 108), harvested by trypsinization, were homogenized in
20 mM K2HPO4, 1 mM EDTA, 10% glycerol and 12 mM thio-
glycerol, pH 7.4, with a Potter Teflon/glass homogenizer, and
centrifuged to obtain crude cytosol and nuclei. Cytosolic ER and
progesterone receptors (PR) were simultaneously estimated by a
double-labelling DCC assay as described (Ronchi et al, 1986).
Nuclear pellets were salt-extracted as described (Cappelletti et al,
1988), and cytosol and nucleosol were incubated overnight with
16a-[125I]-iodo-oestradiol (8150 GBq mmol–1, 5 nM), alone or in
the presence of a 200-fold molar excess of oestradiol. Incubation
was stopped by treatment with a DCC pellet.
pS2 and cathepsin D expression
Total RNA, transferred to a Hybond+ nylon membrane
(Amersham International, Buckinghamshire, UK), was probed
with double-stranded, biotin-labelled (non-radioactive Random
Octamer Labelling System, Tropix, Bedford, MA, USA) pS2
cDNA and 52K-9 cDNA, corresponding to most of the coding
sequence of pS2 and cathepsin D mRNA. All RNA samples were
also probed for 36B4 mRNA, which was used as an internal
control. Blots were revealed by a chemiluminescent method
(Northern Chemiluminescent Detection System, Tropix), based
on streptavidin–alkaline–phosphatase conjugate and a substrate
(CSPD®), which, upon dephosphorylation, emits a light at 477 nm
revealable by autoradiography on Hyperfilm MP (Amersham).
Autoradiographs were densitometrically scanned using an LKB
Ultrascan XL laser densitometer. Densitometric readings were
normalized for 36B4 RNA content, and data were expressed as
relative expression levels.
Gel mobility shift assay
Complementary oligodeoxyribonucleotide strands containing a
consensus ERE (GATCCAGGTCACAGTGACCTGGGCCCG-27
bp) were end-labelled with t [32P]-ATP (110 000 GBq mmol–1) with
the T4 polynucleotide kinase (Amersham). DNA-binding reactions
were carried out in buffer containing 6 ng radiolabelled ERE, 380
fmol of recombinant human ER (Boehringer, Mannheim, Germany),
20 mM HEPES (pH 7.9), 60 mM potassium chloride, 5 mM magne-
sium chloride, 2 mM dithiothreitol, 10% glycerol, 100 mg bovine
serum albumin and the indicated concentrations of drugs in 20 ml
total volume at 20°C for 20 min followed by 15 min additional incu-
bation at 37°C. Thereafter, the protein–DNA complexes were sepa-
rated on 4% native polyacrylamide gels in 90 mM Tris–borate buffer
containing 2.5 mM EDTA, pH 8.3, at a constant current of 25 mA at
room temperature.
Data analysis
Each experimental point represents the mean of four determina-
tions obtained by Latin Square in three separate experiments.
Variations in treated samples were expressed with respect to the
control. Differences between DNA content means were evaluated
by Student’s t-test.
RESULTS
Biological effects of genistein and quercetin
Effects of genistein and quercetin on proliferation of MCF-7
cells
Figure 1 shows the effect of increasing concentrations of genistein
and quercetin (ranging from 0.5 to 20 mM) on the growth of MCF-7
cells cultured for 6 days in medium containing 2% FCS. Genistein
exerted a biphasic effect, stimulating growth (up to 120% of the
control, P < 0.01) at concentrations of less than 5 mM and causing a
dose-dependent inhibition at higher concentrations. Quercetin did
not influence cell growth up to 2.5 mM and dramatically inhibited
growth at higher concentrations. Noteworthy was the lower IC50
value for quercetin (4.9 mM) than for genistein (10 mM).
Effect of genistein and quercetin on hormone- and growth
factor-stimulated growth
The effect of quercetin and genistein on the growth of stimulated
MCF-7 cells was evaluated at 1 mM and 5 mM concentrations,
which do not significantly alter cell growth of unstimulated cells
(Figure 2). Experiments were carried out in serum-free medium.
As already reported in our previous studies (Cappelletti et al,
1993), oestradiol and transforming growth factor a (TGF-a)
caused a statistically significant (P < 0.01) stimulation of MCF-7
cell growth ranging from +50% to +20% respectively.
Quercetin and genistein efficiently and significantly (P < 0.01)
counteracted the stimulation by oestradiol and TGF-a (Figure 2),
which is known to mediate the oestrogenic stimulation of growth
in the cell line.
Table 1 Effect of quercetin and genistein on the expression of steroid
receptors
ER PgR
(fmol mgP–1) (fmol mgP–1)
Control 251a 6
E2 10–8 M 6 252
Quercetin 2.5 mM 245 9
Genistein 5 mM 118 56
Quercetin + E2 98 1
Genistein + E2 13 339
afmol mgP–1 representing the mean of three separate receptor
determinations. Each experimental point was run in triplicate in parallel.
Standard error among the triplicates was always less than 10%.
Table 2 MCF-7 cytoplasmic and nuclear ER content after a 6-day treatment
with phyto-oestrogens
Cytoplasmic Nuclear
ER ER
(fmol mgP–1) (fmol mgP–1)
Control 190a 280
1 mM quercetin 121 335
5 mM genistein 104 670
afmol mgP–1 representing the mean of three separate receptor
determinations. Each experimental point was performed in parallel in
triplicate. Standard error of triplicates was always less than 10%.1152 P Miodini et al
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Effect of genistein and quercetin on the expression of
oestrogen-regulated genes
We then addressed the ability of genistein and quercetin to inhibit
oestradiol-promoted cell stimulation in an attempt to better under-
stand the molecular basis for the anti-oestrogenic action of
flavonoids on MCF-7 cell growth. The expression of ER and PR in
cells treated with oestradiol alone or in combination with 5 mM
genistein and 2.5 mM quercetin is reported in Table 1. Oestradiol
caused a 42-fold induction of PR levels (P < 0.001), whereas geni-
stein triggered a ninefold increase in PR expression (P < 0.001) and
quercetin did not alter PR values. Induction of PR by oestradiol,
and genistein, singly administered, was associated to a down-regu-
lation of ER levels, which instead were not modified by treatment
with quercetin. When the two phyto-oestrogens were combined
with oestradiol, we observed an even stronger induction of PR
(from 6 fmol mgP–1 to 339 fmol mgP–1) by genistein, whereas the
combination of oestradiol and quercetin led to an attenuation of
oestradiol-promoted PR induction (13.5-fold in the combined treat-
ment (P < 0.001) versus 42-fold when cells were treated by oestra-
diol alone). At the 5 mM concentration, which abolished cell growth
stimulation promoted by oestradiol, genistein induced a more than
twofold stimulation of pS2 and cathepsin D transcription rate
(Figure 3). Such stimulation was similar to that obtained by treat-
ment with oestradiol (more than twofold), and the combined treat-
ment resulted in a slightly stronger stimulation (not statistically
different from that obtained with single-agent treatments).
Under the same experimental conditions, treatment with
quercetin did not significantly influence the expression levels of
pS2 and cathepsin D. When quercetin was combined with oestra-
diol, it almost completely counteracted the stimulation of pS2
promoted by oestradiol and caused a 50% reduction of oestradiol-
induced cathepsin D stimulation (Figure 3).
Molecular action of genistein and quercetin
Competition binding studies
The ability of genistein and quercetin to compete for binding to ER
sites under equilibrium conditions and in the presence of a satu-
rating concentration of 16a-[125I]-oestradiol was investigated over
a range of competitor concentrations of 2.5 nM to 25 mM. Genistein
competed with oestradiol for binding to the ER, with a lower
relative affinity occupying as much as 80% of ER sites at the
highest tested concentration (25 mM). In the concentration range
used in our experiments, more than 70% of total receptor sites was
occupied by genistein (Figure 4). In contrast, quercetin, tested over
a similar range of concentrations, did not efficiently compete with
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Figure 1 Effect of various doses (0.5–20 mM) of genistein (•–•) and
quercetin (n–n) on the growth of MCF-7. Cells were plated in 24-well culture
dishes at a cell density of 15 000 cells per well and allowed to attach for 24 h.
Thereafter, 2% FCS medium containing the substances to be tested was
added and changed every 3 days. Experiments were stopped at day 7 when
the cells were still in their exponential phase of growth. Each point is the
average of three independent experiments performed in quadruplicate (Latin
Square)
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Figure 2 Effect of quercetin and of genistein on the growth of MCF-7 cells
treated with oestradiol and growth factors. Cells were plated in 24-well
culture dishes at a cell density of 20 000 cells per well and allowed to attach
for 24 h in complete growth medium. Thereafter, medium was replaced by
MOM3 medium containing the substances to be tested and was changed
every 3 days. Experiments were stopped at day 7 when the cells were still in
their exponential phase of growth. Hatched bars represent treatment with
1 mM quercetin, dotted bars represent treatment with 5 mM genistein, and
open bars represent controls grown in the absence of any treatment or, when
indicated, in the presence of 10 nM 17b-oestradiol or 1 ng ml–1 TGF-a. Each
bar is the mean of three separate experiments ± s.d.
Figure 3 Transcriptional regulation of cathepsin D and pS2 by genistein
and quercetin alone or in combination with oestradiol. Total RNA was
extracted by the Ultraspec-II RNA extraction system from MCF-7 cells
treated for 48 h with 10 nM 17b-oestradiol, 5 mM genistein, or 1 mM quercetin
in 2% DCC-FCS. RNA samples were run on 1% agarose formaldeyde-
denaturing gel, blotted on a nylon membrane (Hybond+, Amersham) and
probed with double-stranded cDNA probes pS2, 52K-9 and 36B4.
Autoradiographs were densitometrically scanned to qualitatively evaluate
pS2 and cathepsin D expression. The graph represents densitometric
determinations of pS2 (open bars) and cathepsin D (closed bars) corrected
for variation in total loaded RNA and expressed in arbitrary unitsEffect of genistein and quercetin on the oestrogen receptor 1153
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oestradiol. It occupied less than 10% of ER sites when tested at
1–2.5 mM concentrations and only 40% of ER sites at the concen-
tration 25 mM (Figure 4).
Effect of genistein and quercetin on steroid receptor
metabolism
MCF-7 cells grown in medium supplemented with 2% FCS were
treated for 6 days with 1 mM quercetin or 5 mM genistein. At the
end of the treatment, cells were harvested by trypsinization and
processed for cytoplasmic and nuclear ER determination. Results
are shown in Table 2. Genistein, and to a lesser extent quercetin,
although unable to interact directly with the oestrogen ligand site,
significantly (P < 0.001) down-regulated cytoplasmic ER levels,
as expected for a true oestrogen agonist, and genistein also
promoted a tighter association of the receptor with the nucleus.
Gel mobility shift assay
To further clarify the molecular basis for the agonistic–antago-
nistic activity of genistein and to understand the mechanism of the
antagonistic activity exerted by quercetin, we performed a gel
mobility assay using purified ER and a labelled double-stranded
ERE consensus sequence (Figure 5). Gel electrophoresis of
samples containing the pure ER preincubated with 10–8 M oestra-
diol and the labelled oligonucleotide revealed the appearance of a
retarded band corresponding to the ER–ERE complex since it was
supershifted by the addition of a specific anti-ER antibody. A less
intense band characterized by similar mobility was observed in
control samples (without oestradiol). Pretreatment of the ER with
genistein, in the presence or in the absence of oestradiol, induced
the formation of a complex characterized by mobility identical to
that obtained in the control and in the oestradiol-treated samples.
The finding indicates that the DNA-binding properties of the
oestradiol–ER complex and of the genistein–ER complex are
indistinguishable and justifies the transcriptional induction of
oestrogen-regulated genes by genistein. However, quercetin,
although unable to compete with oestradiol in binding to the ER,
also determined the formation of a retarded band electrophoreti-
cally indistinguishable from that observed with oestradiol and
whose intensity appeared to be dose-dependent. Such a finding is
therefore in agreement with the previous observation of a tighter
binding of ER in the nucleus upon treatment of cells with
quercetin.
DISCUSSION
We compared the antiproliferative activity of genistein and
quercetin in MCF-7, a typically hormone-sensitive breast cancer
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Figure 5 Gel mobility assay of recombinant ER to the specific consensus sequence (GATCCAGGTCACAGTGACCTGGGCCCG-27-bp). Binding of
radiolabelled ERE in the presence of: (A) 10–8 M oestradiol (lane 1), 10–8 M oestradiol and anti-ER antibody (HC-20, Santa Cruz, CA, USA) (lane 2), a 30-fold
excess of unlabelled ERE (lane 3), 10–8 M oestradiol, and a 30-fold excess of unlabelled aspecific competitor SP1 (lane 4), control without ligand (lane 5); (B)
control without oestradiol (lane 1), genistein 2.5 and 10 mm in the absence (lanes 2 and 3) and in the presence of 10–8 M oestradiol (lanes 4 and 5);
(C) control without oestradiol (lane 1) and 1 and 10 mM quercetin in the absence (lanes 2 and 3) and in the presence of 10–8 M oestradiol (lanes 4 and 5)
Figure 4 Competition by genistein (•–•) and quercetin (*–*) for binding to
cytoplasmic ER sites. Cytosol obtained from MCF-7 cells was incubated
overnight at 0–4°C with 2.5 nM 16a-[125I]-oestradiol alone or in the presence
of increasing amounts (1–10 000-fold molar excess) of 17b-oestradiol (l l–l l).
Binding to the ER was assessed by DCC treatment and direct counting of
protein-bound radioactivitycell line, in order to gain insight into their molecular mechanism of
action at the ER level. Both phyto-oestrogens, when tested at
concentrations that do not affect unstimulated cell growth,
completely abolished stimulation promoted by oestradiol and by
TGF-a, which is known to mediate oestradiol-promoted growth in
such cell lines (Bates et al, 1986; Cappelletti et al, 1986). Based on
our cell growth experiments, an anti-oestrogenic activity, at least
on oestrogen- and TGF-a-mediated cell stimulation, was shown
for both compounds. Such effects were observed at concentrations
of genistein likely to be locally found in breast tissue of subjects
with a high dietary intake of soy (Zava and Duwe, 1997).
In the case of quercetin, the antagonistic activity could also be
evidenced by the expression of oestrogen-regulated genes. In fact,
quercetin did not down-regulate cytoplasmic ER levels, as did
oestradiol and genistein, and also did not increase PR expression,
but it counteracted oestradiol-stimulated PR protein induction.
The biocharacter of genistein and quercetin was also studied by
investigating the expression of pS2 and cathepsin D genes at the
RNA level. The findings on steroid receptor, pS2 and cathepsin D
expression suggest that quercetin has an antagonistic potential not
only on oestradiol-stimulated growth, but also on oestradiol-stim-
ulated gene transcription. Therefore, based on the phenomeno-
logical data collected in our study, genistein could be defined as an
agonistic–antagonist, depending on biological effect and concen-
tration, whereas quercetin appears to behave like a pure oestrogen
antagonist.
The study then addressed the molecular basis for such effects.
Since a common step in the mechanism of action of anti-oestro-
gens is the specific high-affinity binding to the ER, we defined
through competition studies the relative affinities of genistein and
quercetin for ER. The ability of genistein to compete with oestra-
diol for binding to the ER could represent a necessary, but insuffi-
cient condition to exert an agonistic or an antagonistic effect, or,
as frequently happens, a mixed agonistic–antagonistic activity.
However, the lack of competition of quercetin for the oestradiol
binding site prompted us to look for alternative antagonistic mech-
anisms. In fact, it could be hypothesized that the antagonistic
activity is not mediated by a direct interaction with the ER binding
site and may involve other domains of the ER protein, possibly
leading to impairment of dimerization or a steric conformation
with a weaker transcriptional activity.
The initiation of ER-regulated gene transcription requires a tight
and specific interaction of the ER with its responsive element. The
tightness of such an interaction is indirectly reflected by the so-
called nuclear translocation process, whose practical consequence
is recovery of the bulk of receptors in the nuclear (upon high salt
extraction procedures) rather than in the soluble cytoplasmic frac-
tion. In fact, the latter contains only those nuclear receptors
loosely associated to the nucleus and therefore prone to leak into
the cytoplasmic fraction during homogenization in hypotonic
buffer.
We therefore investigated the subcellular localization of the ER
after in vivo treatment with phyto-oestrogens. A tighter nuclear
association of the ER was induced as expected by genistein, but
surprisingly also by quercetin. We further investigated the specific
interaction between the pure ER protein incubated in the presence
of oestradiol and phyto-oestrogens with the specific radiolabelled
ERE sequence. A specific interaction, as suggested by the retarded
band observed in the gels and corresponding to the ER–ERE
complex, was observed in control samples (as already described
by Brown and Sharp, 1990), with an intensity that increased upon
treatment with oestradiol, genistein or quercetin. Based on such
data, we may conclude that genistein binds to the ER at the
oestrogen binding site, and the formed complex interacts specifi-
cally with the ERE, thereby promoting the transcription of oestra-
diol-regulated genes. Quercetin, in contrast, does not bind the
oestrogen binding site but probably interacts with some other sites:
such interaction causes a conformational change in the ER protein,
which leads to an increased binding to the ERE, but the formed
ER–ERE complex is unable to activate transcription. The same
type of interaction could also occur in the presence of oestradiol
and determine a conformational change of the oestrogen-occupied
receptor, which allows interaction with ER but impairs activation
of gene transcription by oestrogens.
We are unable at present to better define the conformational
change induced by quercetin on the free and occupied receptor
protein because electrophoretic mobility of the retarded bands was
indistinguishible. However, it may be hypothesized that the
conformational variation induced by interaction with quercetin
impairs the interaction between the ER–ERE complex and the co-
activator and co-integrator proteins necessary for a productive
contact with the basal transcription machinery. If such a hypoth-
esis is true, molecules like the phyto-oestrogen quercetin may
represent an interesting tool to better understand the interaction
between ER and the numerous nuclear receptor co-activators and
co-repressors recently described (Horwitz et al, 1996).
Of course, such an explanation about the molecular basis of the
agonistic and antagonistic activity of flavonoids is very specula-
tive and takes into account only ER-mediated effects of genistein
and quercetin. Genistein and quercetin both have pleiotropic
biological effects mainly due to their activity on enzymes of the
signal transduction pathway (Singhal et al, 1995) and the enzymes
of energy metabolism (Lang and Racker, 1974). Therefore, it may
not be excluded that, depending on the tested dose, flavonoid-
induced variations in multiple cellular processes may affect
ER-regulated gene transcription and oestradiol-controlled cell
proliferation.
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